Roivant net loss widens 74% on below-the-line costs despite $770M settlement gain

Filed May 20, 2026 · Period ending March 31, 2026 · Compared to 10-K May 29, 2025 · ~2 min read

Key Changes

• high

  Net loss widened 74.3% to $299.8M (from $172.0M) while operating loss narrowed 48.7% to $515.1M (from $1.0B) — the net-income deterioration came from below-the-line items, not operations. A $770M litigation settlement gain was more than offset by $133M income tax expense (vs $48M prior year) and other non-operating costs.

  MD&A: Earnings Quality verify on EDGAR →
• high

  Brepocitinib received FDA Priority Review for dermatomyositis with PDUFA date 3Q 2026 and commercial launch expected by end of September 2026. Phase 3 VALOR met primary endpoint (TIS 46.5 vs 31.2 placebo, p=0.0006) and all nine key secondary endpoints. Addressable market estimate nearly doubled from 37,000 to 70,000 adult DM patients.

  Business: Brepocitinib Regulatory Progress verify on EDGAR →
• high

  Batoclimab discontinued across all indications after two Phase 3 thyroid eye disease trials failed to meet primary endpoints in April 2026. Immunovant recognized $39M in non-cancelable contractual costs and accrued $42.5M total exit liabilities. Company now focuses exclusively on IMVT-1402, its second-generation anti-FcRn antibody.

  Business: Batoclimab Discontinuation verify on EDGAR →